secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0000917520-24-000121
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences adopts Change in Control Severance Program effective Jan 1, 2025, renewing expiring program
--------------------------------------------------------------------------------

- Program covers named executives including CFO Lea Knight, with severance multiple of 2x (1.5x for others) base salary plus target bonus.
- Qualifying termination (without cause or for good reason) within 2 years after a change in control triggers lump-sum severance, prorated bonus, COBRA for 18 months, and outplacement.
- Program term runs through Dec 31, 2025, with automatic extension upon a change in control until 2-year anniversary.
- Benefits subject to general release of claims and potential 'best pay cap' reduction for excise tax under Section 4999.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000121/0000917520-24-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000121/iart-20241212.htm
  HTML page:      https://secwatch.observer/filing/0000917520-24-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer